Ana Paulina Pamplona Sierra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ana Paulina Pamplona Sierra has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Andrés David Aranzazu-Ceballos
Universidad Pontificia Bolivariana
1 shared publication - Daniela Vergara Yanez
Universidad Pontificia Bolivariana, Medellín, Colombia
1 shared publication - Liliana Franco
Laboratorio de Genética Molecular, Universidad de Antioquia, Medellín, Colombia
1 shared publication - Lina María Martínez Sánchez
Universidad Pontificia Bolivariana
1 shared publication - Richard Baquero Rodriguez
Department of Pediatric Nephrology, Antioquia University, Hospital San Vicente Fundación, Medellin 50010, Colombia
1 shared publication
Latest Publications
- Open Access
- 1 January 2024
- Published by SAGE Publications in Global Pediatric Health
- Vol. 11
Primary Thrombotic Microangiopathy in Pediatric Patients
Background. Primary thrombotic microangiopathy includes hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli, atypical hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Methodology. A retrospective study that included patients younger than 18 years diagnosed with primary thrombotic microangiopathy between 2011 and 2021. Results. Thirty patients were included, of which 63% corresponded to a hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli, and 30% to the atypical hemolytic uremic syndrome. The median age was 2.8 years and female sex predominated at 57%. On admission to the emergency room, fever and fatigue were the most frequent symptoms (93%), followed by oliguria and anuria (80%). 48% of patients received hemodialysis during their care. Mortality was estimated at 13%. Conclusion. This study constitutes the largest series of primary thrombotic microangiopathy in the pediatric population of Latin America, where the etiological and clinical behavior of this condition is described.
- 1 January 2024
- Published by SAGE Publications in Global Pediatric Health
- Vol. 11
Open AccessPrimary Thrombotic Microangiopathy in Pediatric Patients
Background. Primary thrombotic microangiopathy includes hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli, atypical hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Methodology. A retrospective study that included patients younger than 18 years diagnosed with primary thrombotic microangiopathy between 2011 and 2021. Results. Thirty patients were included, of which 63% corresponded to a hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli, and 30% to the atypical hemolytic uremic syndrome. The median age was 2.8 years and female sex predominated at 57%. On admission to the emergency room, fever and fatigue were the most frequent symptoms (93%), followed by oliguria and anuria (80%). 48% of patients received hemodialysis during their care. Mortality was estimated at 13%. Conclusion. This study constitutes the largest series of primary thrombotic microangiopathy in the pediatric population of Latin America, where the etiological and clinical behavior of this condition is described.